Bioavailability of Tipranavir/Ritonavir Paediatric Solution vs Capsules

Phase 1, randomised, open-label trial of tipranavir in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration time curve of tipranavir in plasma from 0 to infinity up to 72 hours and Maximum concentration of tipranavir in plasma up to 72 hours. Started Oct 2003; status: completed.